Our findings provide the first evidence that selectively augmenting the endocannabinoid anandamide decreases fear after extinction in a mouse model, and establish the neural locus underlying this behavioral action. In addition, we provide translational evidence from functional neuroimaging and genetic association studies in human subjects, supporting the therapeutic value of FAAH as a target for anxiety disorders.
